Game-changing class of immunotherapy drugs lengthens melanoma survival rates
From Nature, 22 April 2020: When Jedd Wolchok began working in the area of melanoma 20 years ago, the average life expectancy for a patient with advanced disease was six or seven months. Now his waiting room is full of people coming back for their third or fourth year of follow-up, sharing their stories of … Continue reading Game-changing class of immunotherapy drugs lengthens melanoma survival rates